These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31020605)

  • 21. Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells.
    Oh HN; Kwak AW; Lee MH; Kim E; Yoon G; Cho SS; Liu K; Chae JI; Shim JH
    Phytomedicine; 2021 Jan; 80():153355. PubMed ID: 33039730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
    Wang H; Fei Z; Jiang H
    J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
    Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
    Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET.
    Oh HN; Lee MH; Kim E; Kwak AW; Yoon G; Cho SS; Liu K; Chae JI; Shim JH
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32070026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
    Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
    Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1.
    Zhang T; Wang N
    Oncol Res; 2018 Sep; 26(8):1191-1200. PubMed ID: 29386087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells.
    Lee YJ; Kim SY; Lee C
    Mol Med Rep; 2019 Apr; 19(4):3230-3236. PubMed ID: 30816529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
    Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
    Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
    Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
    Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
    Park IH; Kim JY; Jung JI; Han JY
    Invest New Drugs; 2010 Dec; 28(6):791-9. PubMed ID: 19760159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
    Lai XY; Shi YM; Zhou MM
    Kaohsiung J Med Sci; 2023 Jul; 39(7):699-709. PubMed ID: 37057810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.
    Li J; Wang XH; Hu J; Shi M; Zhang L; Chen H
    Cancer Med; 2020 Feb; 9(4):1495-1502. PubMed ID: 31891230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
    Xiao Z; Li M; Zhang X; Rong X; Xu H
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
    Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
    Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.